Evidence map›Paper›PMID 30503695›Full record

ArticleThe International journal on drug policy2019

Estimating HIV and HCV prevalence among people who inject drugs in 5 Ukrainian cities using stratification-based respondent driven and random sampling.

Alexei Zelenev, Portia Shea, Alyona Mazhnaya, Anna Meteliuk, Iryna Pykalo, Ruthanne Marcus, Tatiana Fomenko, Tatiana Prokhorova, Frederick L Altice

Abstract read
In one paragraph

Article in The International journal on drug policy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexei ZelenevYale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, 06510, USA. Electronic address: alexei.zelenev@yale.edu.
Portia SheaYale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, 06510, USA.
Alyona MazhnayaICF Alliance for Public Health in Ukraine, 5 Dilova str. Building 10A, Kyiv 03150, Ukraine; Johns Hopkins Bloomberg School of Public Health, Department of Health, Behavior and Society, 624 N Broadway, Baltimore, MD 21205, USA.
Anna MeteliukICF Alliance for Public Health in Ukraine, 5 Dilova str. Building 10A, Kyiv 03150, Ukraine.
Iryna PykaloUkrainian Institute on Public Health Policy, Mala Zhytomyrska St, 5, Kyiv, 01001, Ukraine.
Ruthanne MarcusYale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, 06510, USA.
Tatiana FomenkoICF Alliance for Public Health in Ukraine, 5 Dilova str. Building 10A, Kyiv 03150, Ukraine.
Tatiana ProkhorovaICF Alliance for Public Health in Ukraine, 5 Dilova str. Building 10A, Kyiv 03150, Ukraine.
Frederick L AlticeYale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, 06510, USA; Yale University School of Public Health, Division of Epidemiology of Microbial Diseases, New Haven, CT, 06510, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
Prison Interventions and HIV Prevention CollaborationR01DA029910 · NIDA · YALE UNIVERSITY · PI FREDERICK LEWIS ALTICE · 2010 to 2026
$7.9M
Expanding Medication Assisted Therapy in Ukraine (ExMAT)R01DA033679 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2012 to 2021
$6.4M
Global Health Fellows and Scholars Research TrainingR25TW009338 · FIC · UNIVERSITY OF CALIFORNIA BERKELEY · PI BARRY, MICHELE, KO, ALBERT ICKSANG · 2012 to 2016
$5.2M
Enhancing Health Outcomes Among HIV+ Substance AbusersK24DA017072 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2003 to 2012
$1.5M
Modeling HIV & Substance Abuse: Correcting Sampling Bias and Cost EffectivenessK01DA037826 · NIDA · YALE UNIVERSITY · PI ZELENEV, ALEXEI · 2014 to 2018
$838k
FIC NIH HHS D43 TW010540FIC NIH HHS R25 TW009338NCATS NIH HHS UL1 TR001863NIDA NIH HHS K01 DA037826NIDA NIH HHS K24 DA017072NIDA NIH HHS R01 DA029910NIDA NIH HHS R01 DA033679
6 · The paper itself

Abstract

backgroundUkraine, a country of 45.5 million people, has one of the most volatile HIV and HCV epidemics in the world. In this paper, we estimate the prevalence of HIV and HCV among PWID in five Ukrainian cities.

methodsA cross-sectional study was conducted in 2014-2015, based on stratified hybrid sampling with random and respondent driven sampling in five cities: Kyiv, Odesa, Mykolaiv, Dnipro and Lviv. Using data on HIV and HCV antibody testing from 1613 respondents, we evaluate selection bias in the sampling methods by analyzing spatial and network patterns of sampling processes. We develop and apply inverse probability weights in order to estimate the HIV and HCV prevalence in each city, as well as in the overall sample.

findingsThe aggregate HIV prevalence for the five cities is 35.1% (95% CI: 29.5%-38.5%) but this varied considerably by city: in Kyiv the HIV prevalence is 26.6% (95% CI: 20.3.8%-33.4%), in Odesa - 38.2% (95% CI: 29.8% and 47.1%), in Mykolaiv - 42.0% (95% CI: 34.3%-49.2%), in Dnipro - 58.8% (95% CI: 52.2%-65.8%), and in Lviv 24.6% (95% CI: 18.8%-30.8%). The aggregate HCV prevalence estimate for the five cities is 58.6% (95% CI: 54.9%-61.7%). The highest HCV prevalence is estimated in Kyiv - 84.8% (95% CI: 78.5%-90.1%). HCV prevalence in Odesa is the lowest and estimated to be 36.5% (95% CI: 29.5%-45.1%), in Mykolaiv - 49.1% (95% CI: 41.5%-57.0%), in Dnipro - 56.1% (95% CI: 50.3%-63.4%) and in Lviv 38.5% (95% CI: 31.8%-45.0%).

conclusionsMonitoring behavioral and health outcomes of PWID on a regular basis is necessary for determining prevention and treatment priorities for HIV and HCV infections in Ukraine and elsewhere. The heterogeneity of the local epidemics provides insights into the best prevention and treatment strategies to be deployed in low-resource settings.

Indexed as

AdultCitiesComorbidityCross-Sectional StudiesEpidemiologic Research DesignFemaleHepatitis CHIV InfectionsHumansMalePrevalenceSubstance Abuse, IntravenousUkraineYoung AdultHCVHIVPrevalencePWIDRespondent-driven samplingSample selection biasUkraine

Identifiers

PMID30503695
PMCPMC6537868

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.